By Kiran Biotech is developing AvidinOX®, a protein-based platform designed to improve site-specific localization of biotinylated compounds. The technology enables covalent anchoring at targeted sites, supporting precision research in molecular imaging, diagnostics, and tissue engineering.
Italy, 1st Jul 2025, Grand Newswire – The Italian biotech startup is exploring a new approach to molecular localization based on covalent anchoring of biotin-tagged compounds.
Kiran Biotech, an Italian research-based company operating in the field of molecular delivery technologies, is developing a novel platform aimed at improving the localization of biotinylated compounds through a proprietary protein-based anchoring mechanism called AvidinOX®.
The platform is designed to explore new ways of enhancing the site-specific retention of molecules, with the goal of improving selectivity and reducing unwanted dispersion in preclinical research and diagnostic settings.
AvidinOX® is a chemically modified avidin derivative that forms stable covalent interactions with tissue proteins at the site of application.
Once anchored, the treated site can selectively bind biotinylated agents delivered systemically.
This concept supports the investigation of modular delivery strategies, where localization and compound activity are decoupled.
Kiran biotech is studying the potential use of this approach in different research domains, including molecular imaging, tissue engineering, and site-preparation for systemically delivered probes or cells.
Initial results from preclinical studies and early-stage research programs suggest promising opportunities for further development.
AvidinOX® has been the subject of publications in peer-reviewed journals, including Oncotarget, Oncology Letters, and Bioorganic & Medicinal Chemistry Letters, where its anchoring behavior and molecular compatibility were explored under experimental conditions.
According to Kiran Biotech’s team, the modularity of AvidinOX® may allow future integration with a range of compatible technologies, including biotin-labeled molecules or probes developed by third-party research groups or pharmaceutical companies.
Its anchoring mechanism, once validated and scaled, could serve as a platform to support localized strategies in various investigational frameworks.
Kiran biotech holds a portfolio of intellectual property protecting the AvidinOX® molecule, its production process, and a broad range of research applications involving localization, targeting, and detection.
The company was recently recognized as one of Italy’s emerging innovators in the biotech sector, and it has received support under Italy’s national innovation funding programs.
The company is currently focused on advancing its R&D pipeline, establishing production scale-up protocols under controlled conditions, and initiating collaborative studies with institutions and private partners.
“We see AvidinOX® as an enabling technology.” says Rita De Santis, CEO of Kiran Biotech.
“Our goal is to provide researchers with tools to better explore localization and selective delivery in a wide range of experimental applications.”
About Kiran Biotech
Kiran Biotech is a privately held Italian company focused on the development of protein-based tools and delivery platforms for use in preclinical research, diagnostics, and biotechnological innovation.
Its mission is to contribute to the evolution of precision strategies through site-specific anchoring technologies.
Media Contact
Organization: IMISEST
Contact Person: Stefano Manzotti
Website: https://imisest.com
Email:
[email protected]
Country:Italy
Release id:30091
Information contained on this page is provided by an independent third-party content provider. Binary News Network and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]
Comments